ALBRIOZA Commercial Launch

Amylyx Select Financial Data Statement of Operations ($ thousands except per share data) Product revenue, net Cost of sales Research and development Selling, general and administrative 1Q23 4Q22 71,428 $ 21,885 5,283 2,821 24,192 22,813 44,006 40,844 Total operating expenses $ 73,481 $ 66,478 Net income (loss) $ 1,573 $ (42,704) Net income (loss) per share - diluted $ 0.02 $ (0.65) Balance Sheet ($ thousands) 1Q23 4Q22 Cash, cash equivalents and short- $ 345,674 $ 346,945 term investments AMYLYX 36

View entire presentation